BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) said that the United States Patent and Trademark Office (USPTO) has approved a patent for its primary cancer.
BiVictriX Therapeutics PLC (AIM:BVX, OTC:BVTXF) founder and CEO Tiffany Thorn speaks to Thomas Warner from Proactive after announcing that the UK-based drug.
Cancer treatment developer BiVictriX Therapeutics has secured a significant patent from the United States Patent and Trademark Office (USPTO), it announced on Wednesday, for its flagship therapeutic asset, BVX001.